Regeneus has a patent portfolio that covers the AdiCell^TM and HiQCell^TM procedures; secretion based and allogeneic products. These patents are being pursued worldwide. Regeneus holds the registered trademark for "AdiCell" and has applied for the "HiQCell" trademark.

Regeneus operates within a favourable regulatory environment. The HiQCell and AdiCell procedures fall outside the requirement to register it as a human or veterinary medicine in Australia due to its being an autologous cell therapy, where the cells are harvested and minimally processed in a single procedure under the supervision of a registered doctor or veterinarian.